Alembic Pharmaceuticals Limited — Q1 FY26 earnings call

Call held 5 Aug 2025

Management summary

Alembic Pharma delivered a steady Q1 FY26, characterized by double-digit growth in international markets which offset a sluggish performance in the domestic branded segment. The company is benefiting from improved gross margins (76.2%) and operating leverage as new facilities ramp up. Management is focused on resolving execution issues in India and scaling the US injectable and complex generic pipeline to sustain growth.

Highlights

  • Total revenue grew 10% YoY to ₹1,711 crores, driven by strong international performance.

  • Net profit increased by 15% YoY to ₹154 crores, with EPS standing at ₹7.85.

  • US business grew 13% despite pricing pressure, supported by volume gains and 4 new launches.

  • Rest of World (RoW) generics saw a robust 21% increase, reflecting strategic geographic expansion.

  • India branded business underperformed with only 5% growth due to execution gaps and UCPMP alignment.

  • EBITDA margin (after R&D) improved to 17%, up from 15.5% in the previous year.

  • R&D expenses rose 26% to ₹145 crores, in line with full-year guidance of ₹600-650 crores.

Key financials

  1. Revenue ₹1,711 Cr +10%YoY
  2. EBITDA Margin (post-R&D) 17%
  3. Net Profit ₹154 Cr +15%YoY
  4. EPS ₹7.85 +14.7%YoY
  5. R&D Expense ₹145 Cr +26%YoY

What they filed

Q1 FY27: revenue up 25.7%, net profit up 11.7% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue1,648 1,693 1,770 1,711 1,910 +16%1,876 +11%1,848 +4%2,150 +26%
EBITDA239 260 271 281 316 +32%292 +12%228 −16%332 +18%
Net profit153 138 157 154 184 +20%132 −4%202 +29%172 +12%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • India Branded Business
    ₹599 Cr Revenue5% Growth
  • US Business
    13% Growth
  • RoW Generics
    21% Growth
  • API Business
    ₹261 Cr Revenue0% Growth

Guidance & targets

Revenue

  • US Business Growth Revenue · FY26 · High confidence 10-15%
    I expect the US business to grow for the full year anywhere between 10% to 15%.

    — Pranav Amin, Managing Director

  • RoW Market Growth Revenue · FY26 · Medium confidence 10-15%
    I expect for the full year, we will grow... close to about 10%-15% at least in the RoW markets.

    — Pranav Amin, Managing Director

Profitability

  • R&D Expense Profitability · FY26 · High confidence ₹600-650 crores
    this is in line with the full year guidance that we gave at the beginning of this year, which is supposed to be around Rs. 600 to Rs. 650 crores in R&D expense.

    — G. Krishnan, CFO

Capex

  • Annual Capex Capex · FY26 · High confidence ₹400 crores
    But we also guided for a CAPEX of about Rs. 400 crores at the beginning of the year.

    — G. Krishnan, CFO

Margin

  • Raw Material Cost Contribution Margin · Ongoing · Medium confidence 25-30%
    So it will be anywhere between 25%-30% depending on which quarter you're looking at... We will continue to be in that range going forward as well.

    — G. Krishnan, CFO

Other

  • Effective Tax Rate (ETR) Other · FY26 · High confidence 17-18%
    I think we will be in the range of 17%-18% overall for the full year.

    — G. Krishnan, CFO

Risks & concerns

  • API Pricing Pressure

    medium

    Pricing erosion in API due to industry-wide phenomena and data transparency issues with Chinese traders.

    Management acknowledged

  • India Execution Gaps

    medium

    Underperformance in domestic branded business due to team alignment and UCPMP norm compliance.

    Both acknowledged

  • US Tariff Uncertainty

    low

    Potential impact of 25% tariffs; management believes pharma is currently exempt but remains watchful.

    Analyst downplayed

Areas of evasion (1)

  • Revenue breakup between non-oral solids and OSDs in the US market.

Q&A highlights

3 direct
India Business Underperformance and Execution Direct
We have to focus more on execution... We are more committed to driving underlying growth through our prescribers and prescriptions for a sales that is more sustainable in the future.

Explains the shift from primary-driven sales to sustainable secondary-driven growth and UCPMP compliance, which caused a temporary slowdown.

Asked by Tushar Manudhane, Motilal Oswal

API Pricing Erosion and Chinese Data Leaks Direct
Now with this data that is getting leaked through Chinese traders, everyone knows what price you're selling it at, to which buyer. And that's really caused a lot of appeal and a lot of uncertainty in terms of our pricing.

Reveals a specific competitive headwind in the API business where transparency in export data is eroding pricing power.

Asked by Damayanti Kerai, HSBC

US Tariffs and Manufacturing Strategy Direct
Increasing manufacturing footprint in the US just because of tariffs is something, in my opinion, not something that we are considering... purely for the de-risk perspective, it doesn't make sense to allocate so much capital.

Management clarifies they will not chase US-based manufacturing despite tariff threats, prioritizing capital allocation over geopolitical de-risking.

Asked by Gagan Thareja, ASK Investment Managers

1 min read 5 chapters

Detailed narrative

International Markets Drive Growth

Alembic's international business was the primary growth engine in Q1 FY26. The US business grew 13% YoY, aided by volume gains and four new product launches, while the Rest of World (RoW) segment surged 21%. Management expects the US to maintain at least 10% growth per quarter for the remainder of the year, supported by a pipeline of 10-15 additional launches.

Domestic Branded Business Undergoes Correction

The India branded business grew by a modest 5% to ₹599 crores, which management termed as 'under-delivery'. The slowdown is attributed to a strategic shift toward stricter sales monitoring (primaries vs. secondaries) and alignment with UCPMP norms. Management is confident that execution gaps will be resolved within months, aiming to return to double-digit growth.

API Segment Faces Pricing and Transparency Headwinds

The API business remained flat at ₹261 crores, impacted by pricing erosion that has persisted for 6-7 quarters. A unique challenge highlighted was the leakage of Indian export data through Chinese traders, which has compromised pricing confidentiality. Management expects a tough couple of quarters before a slow recovery in this segment.

R&D Investment and Pipeline Strategy

R&D spending reached ₹145 crores (8.5% of revenue) and is on track to hit the annual target of ₹600-650 crores. The company is pivoting toward complex injectables and peptides. While they missed the first wave for Semaglutide in the US, they are targeting RoW markets and planning a 'Day 1' launch for Tirzepatide in the US.

Operational Efficiency and Margin Expansion

Gross margins improved to 76.2% due to a better product mix and cost improvement programs. EBITDA margins (post-R&D) stood at 17%, benefiting from improved utilization of new facilities. The company expects further margin expansion as capacity utilization increases in the injectable, oncology, and new OSD facilities.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls